Annexon, Inc. (ANNX) Form 10-Q — Aug 12, 2026
Annexon reported a Q2 2026 net loss of $55.3 million, up 13% from $49.2 million a year earlier, with a six-month net loss of $99.5 million and quarterly loss per share of $0.28. Q2 R&D spending rose 6% to $46.6 million while G&A costs jumped 41% to $10.6 million on higher consulting and stock compensation. The clinical-stage biotech held $209.2 million in cash, equivalents and short-term investments at June 30, 2026, against an accumulated deficit of roughly $1.0 billion, and projects existing capital funds operating expenses into 2028.
Key figures
- Debt Amount
- Up to $200.0 million facility; $50.0 million initial tranche funded July 30, 2026
- Total Assets
- 246068000
- Cash Position
- 209200000
- Interest Rate
- Greater of 1-Month CME Term SOFR plus 4.6% or 7.60%
- Maturity Date
- July 1, 2031, extendable to June 1, 2032 upon milestone achievement
- Shares Outstanding
- 189579134
- H1 2026 net loss
- $99.5 million (vs $103.5 million H1 2025)
- Q2 2026 net loss
- $55.3 million (up 13% YoY from $49.2 million)
- Final payment fee
- 2.50%-6.75% of principal depending on repayment timing
- Ga expense q2 2026
- $10.6 million (+41% YoY)
- Rd expense q2 2026
- $46.6 million (+6% YoY)
- Accumulated deficit
- ~$1.0 billion
- Atm proceeds h1 2026
- $63.8 million net (2024 and 2026 ATM programs combined)
- Net loss per share h1 2026
- -$0.50
- Atm 2026 remaining capacity
- $117.8 million
- Weighted avg shares q2 2026
- 201003269
- Pre funded warrants outstanding
- 29765799
- Net cash used in operations h1 2026
- $94.8 million
Price after filing
Close on the filing date to close N calendar days later (from $5.33). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.